Hearing loss and impaired short-term memory in an Alzheimer's disease mouse model of amyloid-beta pathology

Jafari, Zahra; Afrashteh, Navvab; Kolb, Bryan; Mohajerani, Majid H.

doi:10.1016/j.expneurol.2023.114413

Cited by 7 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detection results showed that the crystal size is 0.030 × 0.500 × 0.610 mm 3 , and the main crystal cell parameters are as follows, a = 7.2995(4), b = 8.6002 (5), and c = 13.0646 (7). Alpha = 102.669(2), beta = 94.052(2), gamma = 100.705 (2), and the molecular number in the unit cell (Z) is one. This belongs to the triclinic crystal system, space group P1, and the crystal density (Dx) is 1.305 g cm −3 .…”

Section: The Crystal Structure Of Dl0410mentioning

confidence: 99%

“…Alzheimer's disease (AD), the most common type of dementia in elderly people [1], is a progressive neurodegenerative disorder of the brain marked by the progressive loss of short-term memory [2] and impairment of language function [3], followed by spatial discrimination disorder [4], agnosia [5], and even changes in personality and behavior as the disease progresses [6,7]. Presently, this illness impacts over 30 million individuals globally.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Structural Basis of DL0410, a Novel Multi-Target Candidate Drug for the Treatment of Alzheimer’s Disease

Liu,

Zhao,

Huls

et al. 2023

Crystals

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a complicated disease for which there are still no ideal one-target drugs, while multi-target drugs are closer to ideal drugs and will provide new solutions for the clinical treatment of AD. DL0410 is a promising multi-target drug candidate for AD treatment that is not only a significant inhibitor against both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) but also an antagonist of histamine H3 receptor (H3R), and its therapeutic efficacy in treating cognitive dysfunction has been validated in a series of AD-related animal models, including scopolamine-induced mice, D-galactose-induced and Aβ-induced mice, and APP/PS1 and SAMP8 mice. Although the structure of DL0410 has been analyzed using various detection techniques, such as MS and NMR, its three-dimensional crystal structure still requires further confirmation. In this study, the crystal of DL0410 was grown in aqueous solution, and its structure was detected using the X-ray diffraction method. The crystal data, atomic coordinates, bond lengths, angles, and hydrogen bonds of DL0410 were obtained. Its stability was proven by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Based on this study, the molecular docking of DL0410 with AChE, BuChE, and H3R was performed to uncover their interaction mechanisms and explain their bioactivities. This study provides important information for new multi-target drug design and the research and development of new drugs for AD treatment.

show abstract

Section: The Crystal Structure Of Dl0410mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Structural Basis of DL0410, a Novel Multi-Target Candidate Drug for the Treatment of Alzheimer’s Disease

Liu,

Zhao,

Huls

et al. 2023

Crystals

View full text Add to dashboard Cite

show abstract

“…(Conway et al, 2009; Kral et al, 2016). Animal studies also show that auditory deprivation leads to various neural and behavioural effects on the auditory system (e.g., dystrophic changes, reduced dynamic range, temporal sensitivity, firing rate, cortical dynamics, neural inhibition, cell density and binaural advantage) and memory processing (e.g., diminished hippocampal neurogenesis and impaired spatial learning and memory) (Chang et al, 2019; Jafari et al, 2023; Kral et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

A systematic review of altered resting‐state networks in early deafness and implications for cochlear implantation outcomes

Jafari,

Kolb,

Mohajerani

2024

Eur J of Neuroscience

Self Cite

View full text Add to dashboard Cite

Auditory deprivation following congenital/pre‐lingual deafness (C/PD) can drastically affect brain development and its functional organisation. This systematic review intends to extend current knowledge of the impact of C/PD and deafness duration on brain resting‐state networks (RSNs), review changes in RSNs and spoken language outcomes post‐cochlear implant (CI) and draw conclusions for future research. The systematic literature search followed the PRISMA guideline. Two independent reviewers searched four electronic databases using combined keywords: ‘auditory deprivation’, ‘congenital/prelingual deafness’, ‘resting‐state functional connectivity’ (RSFC), ‘resting‐state fMRI’ and ‘cochlear implant’. Seventeen studies (16 cross‐sectional and one longitudinal) met the inclusion criteria. Using the Crowe Critical Appraisal Tool, the publications' quality was rated between 65.0% and 92.5% (mean: 84.10%), ≥80% in 13 out of 17 studies. A few studies were deficient in sampling and/or ethical considerations. According to the findings, early auditory deprivation results in enhanced RSFC between the auditory network and brain networks involved in non‐verbal communication, and high levels of spontaneous neural activity in the auditory cortex before CI are evidence of occupied auditory cortical areas with other sensory modalities (cross‐modal plasticity) and sub‐optimal CI outcomes. Overall, current evidence supports the idea that moreover intramodal and cross‐modal plasticity, the entire brain adaptation following auditory deprivation contributes to spoken language development and compensatory behaviours.

show abstract

“…In addition, murine studies have shown a link between Alzheimer's disease and peripheral neuropathy in which the overexpression of APP results in dysfunction of both small and large peripheral nerve fibers [39]. Further, Aβ is associated with hearing loss, likely due to effects on the auditory nerve [40]. A reduced acoustic startle response and peripheral hearing loss are present in the 5xFAD mouse model of Alzheimer's disease [41].…”

Section: Introductionmentioning

confidence: 99%

Amyloid-β Effects on Peripheral Nerve: A New Model System

Stecker,

Srivastava,

Reiss

2023

IJMS

View full text Add to dashboard Cite

Although there are many biochemical methods to measure amyloid-β (Aβ)42 concentration, one of the critical issues in the study of the effects of Aβ42 on the nervous system is a simple physiological measurement. The in vitro rat sciatic nerve model is employed and the nerve action potential (NAP) is quantified with different stimuli while exposed to different concentrations of Aβ42. Aβ42 predominantly reduces the NAP amplitude with minimal effects on other parameters except at low stimulus currents and short inter-stimulus intervals. The effects of Aβ42 are significantly concentration-dependent, with a maximum reduction in NAP amplitude at a concentration of 70 nM and smaller effects on the NAP amplitude at higher and lower concentrations. However, even physiologic concentrations in the range of 70 pM did reduce the NAP amplitude. The effects of Aβ42 became maximal 5–8 h after exposure and did not reverse during a 30 min washout period. The in vitro rat sciatic nerve model is sensitive to the effects of physiologic concentrations of Aβ42. These experiments suggest that the effect of Aβ42 is a very complex function of concentration that may be the result of amyloid-related changes in membrane properties or sodium channels.

show abstract

Hearing loss and impaired short-term memory in an Alzheimer's disease mouse model of amyloid-beta pathology

Cited by 7 publications

References 46 publications

The Structural Basis of DL0410, a Novel Multi-Target Candidate Drug for the Treatment of Alzheimer’s Disease

The Structural Basis of DL0410, a Novel Multi-Target Candidate Drug for the Treatment of Alzheimer’s Disease

A systematic review of altered resting‐state networks in early deafness and implications for cochlear implantation outcomes

Amyloid-β Effects on Peripheral Nerve: A New Model System

Contact Info

Product

Resources

About